Shop by goal
Popular compounds
Research resources
Recently viewed
Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.
Shop
Learn
Company
Support
Ways to Pay
Shop by Compound
Shop by Goal
Ships worldwide
Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.
All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.
Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.
© 2026 New-U Research Compounds · new-u.io · @new.u.io
Semaglutide
Pick your pack · how long it lasts
At 1.70 mg/wk — select pack size
2 single vials minimum for standalone shipping — or add samples to any pack
Lab-direct quality — full packs or single-vial samples
Every batch ships straight from the lab that synthesises it — sealed, tamper-evident, and HPLC-verified to >99% purity with a batch-linked Certificate of Analysis. Buying direct means you pay the lab-direct rate on every vial, with nothing stacked on top.
Order a full sealed 10-vial research pack for a complete study supply, or add a single-vial sample alongside your pack to trial a new compound first. Same lab, same batch, same verified purity — scaled to whatever your research needs.
What It's Researched For
In plain terms, semaglutide is the single-target GLP-1 compound most studied for appetite, weight and blood sugar. Here is what that looks like across the research.
Appetite & cravings
In human trials, studied for turning down hunger signals in the brain so people feel full sooner and eat less.
Weight research
Large clinical studies investigate steady, substantial body-weight reduction over about a year of once-weekly use.
Blood-sugar control
Human studies look at smoother blood sugar after meals, with a low chance of dropping it too low.
Heart-health research
Clinical research explores fewer major heart events in adults carrying extra weight, even without diabetes.
Once-a-week convenience
Because it stays active for roughly a week, research uses a single weekly injection rather than daily dosing.
Overview
Semaglutide is a long-acting GLP-1 receptor agonist with 94% homology to native human GLP-1, engineered for once-weekly dosing and clinically validated for weight loss and type 2 diabetes.
Semaglutide is a 31-amino-acid research peptide that mimics GLP-1, a natural gut hormone released after meals. GLP-1 signals the pancreas to release insulin, slows gastric emptying, and contributes to satiety signalling in the brain.
Native GLP-1 is broken down within two minutes in vivo. Semaglutide uses three engineered modifications, a single amino-acid substitution, a protein-binding fatty acid chain, and a protective swap at position 34, to remain in circulation for approximately a week per dose.
Published research reports an average 14.9% body-weight reduction at 68 weeks with weekly Semaglutide, plus cardiovascular-outcome benefit in subsequent studies. It is supplied here as a sterile lyophilised powder for in-vitro and preclinical research only.
Mechanism of Action
Semaglutide activates the GLP-1 receptor on pancreatic β-cells, the stomach, and the brain - raising insulin only when blood sugar is high, slowing digestion, and suppressing appetite.
Semaglutide design (Journal of Medicinal Chemistry, 2015) carries three specific modifications relative to native GLP-1(7-37): an Aib substitution at position 8 (DPP-IV resistance), an Arg substitution at position 34, and a Lys26 acylation with a C18 fatty diacid via a γGlu/mini-PEG (AEEA) spacer. The fatty chain binds reversibly to serum albumin, keeping the peptide in circulation and protecting it from enzymatic degradation. Steady state is reached in 4-5 weeks, and elimination is primarily through proteolytic cleavage and β-oxidation of the fatty chain, no CYP-mediated drug interactions.
Common Questions People Are Asking
What is semaglutide?
Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist — the peptide best known as the active ingredient in Novo Nordisk's Ozempic and Wegovy. Semaglutide is the research-grade form of this semaglutide peptide, supplied as a lyophilised powder strictly for in-vitro and preclinical laboratory research. It is NOT Ozempic or Wegovy, is not an approved medicine, and is not for human use.
How does semaglutide work?
In the research literature semaglutide binds and activates the GLP-1 receptor, which slows gastric emptying, acts on hypothalamic appetite centres, and enhances glucose-dependent insulin secretion. The fatty-acid/albumin modification extends its half-life to about a week. These are mechanisms described in published studies of the molecule, not human-use guidance — Semaglutide is supplied for research only.
Is Semaglutide the same as Ozempic or Wegovy?
It is the same active peptide (semaglutide), but it is NOT the same product. Ozempic and Wegovy are FDA-approved, prescription, sterile finished pharmaceuticals manufactured under cGMP. Semaglutide is an unapproved, research-grade lyophilised powder sold for laboratory research use only — not for human consumption, and not a substitute for any prescribed medication.
Is semaglutide safe?
As an approved prescription medicine, semaglutide has been extensively studied in human trials under medical supervision. That clinical record does NOT extend to research-grade material: Semaglutide is unapproved, is not manufactured as a sterile human drug, and has no human safety assurances. New-U supplies it for laboratory research only and makes no human-use or safety claims.
How is Semaglutide different from native GLP-1?
Semaglutide shares 94% of its sequence with human GLP-1 but has three engineered modifications: an Aib substitution at position 8 that blocks degradation by DPP-IV, an Arg at position 34, and a C18 fatty diacid attached to Lys26. The fatty acid binds to albumin, extending half-life from ~2 minutes to ~7 days.
Why does Semaglutide produce larger body-composition effects than first-generation GLP-1 agonists?
Semaglutide reaches meaningful GLP-1 receptor occupancy in the hypothalamus, where it directly suppresses appetite, while also slowing gastric emptying. The combined central and peripheral effects produce a much larger and more durable energy-balance shift than earlier GLP-1 agonists could achieve.
Semaglutide vs tirzepatide — what is the difference?
Semaglutide activates a single receptor (GLP-1), while tirzepatide is a dual agonist that adds the GIP receptor on top of GLP-1. In the head-to-head SURMOUNT-5 trial (NEJM 2025) tirzepatide produced larger mean body-weight reduction than semaglutide (20.2% vs 13.7% at 72 weeks), although semaglutide carries the broader cardiovascular- and kidney-outcomes dataset to date. Both are described here only as descriptive research context, and each is supplied as unapproved, research-grade material for laboratory use, not for human use.
Can semaglutide be combined with cagrilintide?
In the research literature the two are studied together as CagriSema, because semaglutide (a GLP-1 agonist) and cagrilintide (an amylin/calcitonin-receptor agonist) act on distinct, additive appetite circuits. The Phase 3 REDEFINE 1 trial (NEJM 2025) of that co-formulation reported a larger mean body-weight reduction than either component alone. This is descriptive clinical-trial context for the molecules, not a protocol for any use of this research-grade material.
Is Semaglutide an approved medicine?
No. Semaglutide is supplied as a research-grade lyophilised powder for in-vitro and preclinical research only. It is not a licensed pharmaceutical product and is not a substitute for any prescribed medication.
How should Semaglutide be stored?
Store the lyophilised powder in a freezer at −20 °C. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C and protect from light. Avoid repeated warming and cooling cycles, as the fatty acid tail is sensitive to prolonged heat exposure.
What happens when you stop taking GLP-1s?
In the published clinical literature on the reference drug (for example the STEP-1 extension study of semaglutide), discontinuing a GLP-1 receptor agonist is followed by the return of appetite signalling and gradual regain of much of the lost body weight over roughly a year, because the receptor stimulation that slowed gastric emptying and curbed appetite is withdrawn. Those observations come from trials of the approved medicines in human subjects — Semaglutide is an unapproved research-grade peptide supplied for laboratory research only and is not for human use.
Where can I buy Semaglutide?
Right here — Semaglutide is supplied directly by New-U Research Compounds on this page. Every batch is independently third-party tested to >99% HPLC purity with a batch-linked Certificate of Analysis, supplied as lyophilised research-grade material, and shipped direct from source worldwide in discreet, tracked packaging. Strictly for laboratory research use only — not for human use.
How much does Semaglutide cost?
Semaglutide pricing is shown live on this page, per pack size — 10-vial research packs as standard, with single-vial sample options on selected compounds. Larger vial strengths lower the per-mg cost, every order includes the batch Certificate of Analysis, and shipping is free on orders over $300.
Is Semaglutide third-party tested?
Yes. Every Semaglutide batch is verified by independent laboratories (Janoshik Analytics and Freedom Diagnostics) for identity and purity, with a batch-linked Certificate of Analysis confirming >99% purity by HPLC. Every order ships with its COA, and current batch certificates are published on our COA page.
How do I buy Semaglutide?
Add the Semaglutide pack size you need to your cart and check out: enter your shipping details, then choose your payment method — cryptocurrency or card — on the next step. Every order ships with its batch Certificate of Analysis (COA). Semaglutide is supplied strictly for laboratory research use only, not for human or veterinary use.
What payment methods can I use to buy Semaglutide?
At checkout you can pay by cryptocurrency (BTC, ETH, SOL, LTC, USDC, USDT and more) or by card, each handled by a dedicated secure payment provider. You choose your method after confirming your order.
How fast is shipping, and do you ship worldwide?
Yes — we ship worldwide in discreet, unmarked, temperature-stable, tracked packaging. Delivery typically takes 6–14 business days, and shipping is free on orders over $300.
Is it legal to buy Semaglutide?
In the United States, Semaglutide is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction — buyers are responsible for compliance in their own region.
Pharmacokinetics
Research-Observed Effects
Published Research Context
In the published clinical literature for the reference drug, subcutaneous semaglutide was titrated gradually to limit gastrointestinal effects — for weight-management research the STEP programme escalated from 0.25 mg once weekly to a 2.4 mg maintenance level over roughly 16 weeks, while the diabetes (SUSTAIN) programme used 0.5–2.0 mg weekly. These figures describe the escalation schedules reported in published trials of the approved medicine; they are recorded here as research context only.
Stacking Compatibility
Compatible compounds
Avoid combinations
Side Effects (Observed in Literature)
Common
Rare
Dose-dependent
Evidence Tier
Overall: Tier 1: Human clinical
Semaglutide is among the most extensively characterised metabolic peptides, with multiple large randomised human outcome trials for the reference drug. The research-grade material supplied here is unapproved and is not the finished pharmaceutical studied in those trials.
Tier 1 · Human clinical
Source References & Further Reading
Last reviewed: 16 June 2026 · New-U Research Compounds
Key Characteristics
Specifications
About Semaglutide: Long-Acting GLP-1 Receptor Agonist Research Compound
Semaglutide has become one of the most well-studied metabolic peptides in published research, and the reference GLP-1 receptor agonist against which newer compounds such as tirzepatide and the CagriSema combination are benchmarked. Its design took decades to work out how to make GLP-1, a hormone the body destroys in minutes, survive long enough to be useful as a once-weekly research probe. The published answer was to anchor the peptide to serum albumin via a C18 fatty-diacid tail.
Published research reports a 14.9% average body-weight reduction at 68 weeks (STEP-1, NEJM 2021) and a 20% reduction in major adverse cardiovascular events independent of diabetes status (SELECT, NEJM 2023). More recent outcome research extends the picture to organ-protection endpoints: the FLOW trial (NEJM 2024) reported reduced kidney-disease progression, and the SOUL trial (NEJM 2025) reported cardiovascular benefit with the oral (SNAC) formulation.
For researchers, Semaglutide is a benchmark GLP-1 receptor agonist for studying incretin biology, appetite regulation, and cardiometabolic effects of gut-brain signalling. The material supplied here is lyophilised Semaglutide acetate for in-vitro and preclinical research only, it is not a licensed pharmaceutical product, and nothing on this page constitutes medical advice.
Customer Reviews
No customer reviews yet — be the first to share your experience.
More in Metabolic / Fat Loss
Semaglutide vs related Metabolic / Fat Loss compounds
Descriptive catalog comparison for research sourcing decisions — not dosing guidance. All compounds are for laboratory research use only.
More on Semaglutide
Part of the Metabolic & GLP-1 research research area — explore related compounds, guides and sources.